DCT

3:25-cv-02049

Janssen Sciences Ireland UnLtd Co v. Laurus Labs Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:25-cv-02049, D.N.J., 03/24/2025
  • Venue Allegations: Venue is based on Defendant Laurus USA having its principal place of business and a regular and established place of business in New Jersey. For Defendant Laurus India, venue is alleged based on its collaboration with its U.S. agent in New Jersey and its status as a foreign company that may be sued in any judicial district.
  • Core Dispute: Plaintiffs allege that Defendants' planned generic version of the HIV-1 treatment COMPLERA®, filed under an Abbreviated New Drug Application (ANDA), infringes three U.S. patents covering the drug's specific formulation and manufacturing processes.
  • Technical Context: The technology involves a fixed-dose combination therapy for HIV-1, addressing the pharmaceutical challenge of combining multiple active ingredients with chemical incompatibilities into a single, stable, and effective oral tablet.
  • Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a Paragraph IV Notice Letter from Defendants, which stated their intent to market a generic version of COMPLERA® prior to patent expiration. The complaint notes that Defendants refused to provide detailed manufacturing information pre-suit, and it references prior litigation involving two of the patents-in-suit against a different generic manufacturer.

Case Timeline

Date Event
2005-05-26 Earliest Priority Date for '752 and '291 Patents
2010-11-19 Priority Date for '102 Patent
2012-01-24 '752 Patent Issued
2013-12-31 '291 Patent Issued
2020-12-08 '102 Patent Issued
2025-02-14 Plaintiffs Received Paragraph IV Notice Letter
2025-03-24 Complaint Filing Date
2025-12-09 Defendants' Alleged Intended Launch Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,857,102 - "Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate"

  • Patent Identification: U.S. Patent No. 10,857,102, "Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate," issued December 8, 2020.

The Invention Explained

  • Problem Addressed: The patent addresses the chemical instability that arises when formulating the HIV drugs tenofovir disoproxil fumarate (TDF) and rilpivirine HCl in a single tablet. The presence of rilpivirine HCl was found to accelerate the degradation of TDF, making prior art "co-wet granulation" methods unsuitable for a clinically viable combination product '102 Patent, col. 2:25-30 Compl. ¶44
  • The Patented Solution: The invention solves this stability problem by physically separating the incompatible active ingredients into a multilayer tablet '102 Patent, abstract Specifically, the patent describes a bilayer tablet where a first layer contains rilpivirine HCl and a second, separate layer contains TDF along with emtricitabine '102 Patent, col. 2:60-65 '102 Patent, Fig. 1 This structure prevents the chemical interaction between rilpivirine HCl and TDF while allowing all three drugs to be delivered in a single dosage form.
  • Technical Importance: This formulation technology was essential for creating COMPLERA®, a successful once-daily, single-tablet regimen for HIV treatment, which improves patient dosing convenience and compliance compared to multi-tablet regimens '102 Patent, col. 2:15-21

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 Compl. ¶82
  • The essential elements of independent claim 1 are:
    • A tablet comprising a first layer and a second layer,
    • wherein the first layer consists of 27.5 mg rilpivirine HCl, 60.0 mg microcrystalline cellulose, 189.8 mg lactose monohydrate, 3.3 mg povidone, 0.4 mg polysorbate 20, 16.1 mg croscarmellose sodium, and 3.0 mg magnesium stearate;
    • and the second layer consists of 200.0 mg emtricitabine, 300.0 mg tenofovir disoproxil fumarate, 150.0 mg microcrystalline cellulose, 80.0 mg lactose monohydrate, 50.0 mg pregelatinized starch, 60.0 mg croscarmellose sodium, and 10.0 mg magnesium stearate.
  • The complaint alleges infringement either literally or under the doctrine of equivalents Compl. ¶82

U.S. Patent No. 8,101,752 - "Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile"

  • Patent Identification: U.S. Patent No. 8,101,752, "Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile," issued January 24, 2012.

The Invention Explained

  • Problem Addressed: The complaint states that prior to the invention, known methods for manufacturing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile ("PBN-II"), a key chemical building block for rilpivirine, were unsuitable for commercial-scale production Compl. ¶3 A prior art process described in the patent liberated methyl mercaptane, a toxic and highly odorous byproduct that posed significant purification challenges, making it impractical for large-scale manufacturing '752 Patent, col. 3:25-32
  • The Patented Solution: The patent discloses a new, scalable synthetic process for making PBN-II. The claimed method involves condensing a guanidine derivative with an alkoxymethylene malonic acid ester, followed by a dealkoxycarbonylation step to yield the final PBN-II product '752 Patent, abstract '752 Patent, col. 4:6-33 This process avoids the problematic reagents and byproducts of the prior art.
  • Technical Importance: The invention provided a commercially viable pathway to manufacture rilpivirine, enabling the production of sufficient quantities of COMPLERA® to meet patient needs Compl. ¶53

Key Claims at a Glance

  • The complaint asserts infringement of at least Claim 1 Compl. ¶113
  • The essential elements of independent claim 1 are:
    • A process for preparing the compound PBN-II (formula I),
    • which comprises condensing a guanidine of formula (III) with an alkoxymethylene malonic acid ester of formula (IV),
    • followed by a dealkoxycarbonylation step to obtain the final product.
  • The complaint reserves the right to assert other claims Compl. ¶113

U.S. Patent No. 8,618,291 - "Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile"

  • Technology Synopsis: The '291 Patent, a continuation of the '752 Patent, is also directed to a process for manufacturing PBN-II, the key intermediate for the HIV drug rilpivirine. The invention provides a reproducible and economical method suitable for commercial-scale production, addressing the shortcomings of prior art manufacturing processes Compl. ¶¶3, 47, 69
  • Asserted Claims: At least claims 1 and 17 are asserted Compl. ¶126
  • Accused Features: Plaintiffs allege that Defendants intend to use the process claimed in the '291 Patent to manufacture the PBN-II that is incorporated into the rilpivirine active pharmaceutical ingredient (API) contained in their proposed generic product Compl. ¶52

III. The Accused Instrumentality

Product Identification

  • The accused product is Defendants' generic emtricitabine, rilpivirine, and tenofovir disoproxil fumarate tablets, for which Defendants submitted ANDA No. 220232 to the FDA for approval Compl. ¶2

Functionality and Market Context

  • The accused product is a generic version of Plaintiffs' "highly successful COMPLERA®" brand drug, a fixed-dose combination tablet used as a complete regimen for the treatment of HIV-1 infection Compl. ¶¶2-3 The complaint alleges the proposed product is a bilayer tablet containing the same three active pharmaceutical ingredients as COMPLERA® Compl. ¶77 Defendants seek to market this product as a lower-cost generic alternative, intending to launch on or after December 9, 2025, upon receiving FDA approval Compl. ¶2 Compl. ¶59
  • No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'102 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A tablet comprising a first layer and a second layer... The proposed Laurus ANDA Product is alleged to be a bilayer tablet. ¶77 col. 24:32-48
...wherein the first layer consists of 27.5 mg rilpivirine HCl, 60.0 mg microcrystalline cellulose, 189.8 mg lactose monohydrate, 3.3 mg povidone, 0.4 mg polysorbate 20, 16.1 mg croscarmellose sodium, and 3.0 mg magnesium stearate; The complaint alleges that the proposed product contains 27.5 mg of rilpivirine hydrochloride, but that certain excipients and their amounts vary from those claimed. It is alleged that the different ingredients perform substantially the same function. ¶77; ¶78 col. 24:34-40
...and the second layer consists of 200.0 mg emtricitabine, 300.0 mg tenofovir disoproxil fumarate, 150.0 mg microcrystalline cellulose, 80.0 mg lactose monohydrate, 50.0 mg pregelatinized starch, 60.0 mg croscarmellose sodium, and 10.0 mg magnesium stearate. The complaint alleges that the proposed product contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, but that certain excipients and their amounts vary from those claimed. It is alleged that the different ingredients perform substantially the same function. ¶77; ¶78 col. 24:41-48

Identified Points of Contention ('102 Patent)

  • Scope Questions: Claim 1 uses the term "consists of," which is legally restrictive and generally prohibits the presence of any unlisted ingredients. The complaint alleges that the accused product's excipients and amounts "vary from those claimed" Compl. ¶77 This raises the question of whether there can be literal infringement. The analysis will likely focus on whether the differences are substantial enough to avoid infringement under the doctrine of equivalents.
  • Technical Questions: A key question for an equivalents analysis will be factual and technical: do the alternative excipients allegedly used in the accused product perform "substantially the same function, in substantially the same way, with substantially the same results" as the specific excipients recited in the claim? Compl. ¶78

'752 Patent Infringement Allegations

  • The complaint does not provide sufficient detail for a claim-chart analysis of the process claims of the '752 patent. The infringement theory is based on 35 U.S.C. § 271(g), which makes it an act of infringement to import, offer to sell, sell, or use within the U.S. a product which is made by a process patented in the U.S. Compl. ¶113 The complaint alleges, on information and belief, that Defendants intend to use the processes claimed in the '752 and '291 patents to prepare the rilpivirine API that will be formulated into the accused product and imported Compl. ¶¶52, 69 This belief is supported by Defendants' alleged refusal to provide manufacturing information and by a patent application published by Laurus Compl. ¶¶67, 70

Identified Points of Contention ('752 Patent)

  • Evidentiary Questions: The central issue will be determining the actual manufacturing process used by Defendants. The complaint invokes the statutory presumption of infringement under 35 U.S.C. § 295, which can shift the burden of proof to the defendant if they fail to provide information about their process after a court order Compl. ¶113 The dispute will likely center on discovery battles over access to Defendants' confidential manufacturing processes.

V. Key Claim Terms for Construction

  • The Term: "consists of"
  • Context and Importance: This term appears in Claim 1 of the '102 Patent to define the exact composition of the tablet's two layers. As a "closed" term in patent law, it typically excludes any unlisted ingredients. Practitioners may focus on this term because the complaint alleges the accused product's excipients and amounts "vary from those claimed," making the interpretation of this term critical to the literal infringement analysis and a gateway to the doctrine of equivalents argument Compl. ¶77
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: While the term itself is restrictive, a party arguing for infringement by equivalents may point to the specification's emphasis on the function of the bilayer structure-to separate incompatible APIs-rather than the specific identity of every excipient. The patent's background section focuses on solving the chemical stability problem of TDF in the presence of rilpivirine HCl '102 Patent, col. 2:25-30, which could suggest that minor, non-functional variations in excipients should not defeat an infringement claim.
    • Evidence for a Narrower Interpretation: The claim language itself, with its highly specific list of ingredients and exact weights (e.g., "189.8 mg lactose monohydrate"), provides strong evidence that the inventors intended to claim a very precise and closed formulation '102 Patent, col. 24:32-48 The use of such precise figures suggests that any deviation, particularly the substitution of different excipients, falls outside the literal scope of the claim.

VI. Other Allegations

  • Indirect Infringement: For the '102 Patent, the complaint alleges that Defendants' commercial manufacture, importation, and sale of the accused product will induce and contribute to infringement Compl. ¶¶82, 97, 102 For the '752 and '291 process patents, the primary allegation is infringement via importation under 35 U.S.C. § 271(g), though the prayer for relief also requests declarations of inducement and contribution Compl. prayer (e) Compl. prayer (h)
  • Willful Infringement: The complaint alleges that Defendants' infringement of all three patents-in-suit will be willful Compl. ¶¶115, 128 Compl. prayer (f) Compl. prayer (i) The basis for this allegation is Defendants' alleged actual and constructive notice of the patents prior to submitting their ANDA, as well as alleged knowledge from prior litigation involving the process patents Compl. ¶¶71, 114, 127

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of claim scope versus equivalents: for the '102 formulation patent, can infringement be established under the doctrine of equivalents given the restrictive "consists of" claim language and the accused product's alleged use of different excipients, or will the precise recitation of ingredients and weights preclude such a finding?
  • A key evidentiary question will be one of process identification: for the '752 and '291 process patents, what manufacturing process do Defendants actually use to synthesize the rilpivirine API? The outcome may turn on whether Plaintiffs can obtain this information through discovery or successfully leverage the statutory presumption of infringement under 35 U.S.C. § 295.
  • A final question will be one of intent: does Defendants' decision to proceed with an ANDA filing despite alleged knowledge of the patents and their refusal to provide manufacturing information pre-suit constitute the "egregious" conduct necessary to support a finding of willful infringement and potential enhanced damages?
Loading Complaint